A phase II study of ME2136 (Asenapine Maleate) plus standard antiemetic therapy for patients, including diabetic patients, receiving cisplatin-based chemotherapy.
Asenapine maleate
CINV
Cisplatin
ME2136
Journal
Investigational new drugs
ISSN: 1573-0646
Titre abrégé: Invest New Drugs
Pays: United States
ID NLM: 8309330
Informations de publication
Date de publication:
26 Oct 2024
26 Oct 2024
Historique:
received:
14
08
2024
accepted:
04
10
2024
medline:
26
10
2024
pubmed:
26
10
2024
entrez:
26
10
2024
Statut:
aheadofprint
Résumé
Olanzapine combined with the neurokinin-1 receptor antagonist, palonosetron and dexamethasone is the standard treatment for chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC). However, the use of olanzapine poses challenges in patients with diabetes mellitus (DM) due to the potential risk of hyperglycemia. ME2136, antipsychotic similar to olanzapine, is associated with a lower risk of hyperglycemia. This study investigated the antiemetic efficacy and safety of ME2136 for HEC. This single-arm phase 2 study examined the safety and efficacy of ME2136 5 mg for 4 days in combination with triplet-combination antiemetic therapy. Two cohorts were established for the safety assessment: DM and non-DM. Eligible patients had malignant tumors and were receiving cisplatin-based chemotherapy for the first time. The primary endpoint was the complete response (CR) rate, defined as the percentage of patients without vomiting and not requiring rescue medications in the delayed phase (24-120 h). Between December 2020 and January 2022, 40 patients were enrolled, with 20 in each cohort. All patients were included in the safety analysis and 35 in the efficacy analysis. The CR rate in the delayed phase was 71.4% [60% CI 63.1-78.6%] for all patients, 66.7% in the DM cohort, and 76.5% in the non-DM cohort. No treatment-related adverse events ≥ grade 3, including hyperglycemia, were reported. ME2136, when combined with standard triplet-combination antiemetic therapy, is expected to exert similar antiemetic effects to the standard treatment for CINV due to HEC. Currently, ME2136-02 trial is underway to examine the safety and efficacy of triplet-combination antiemetic therapy and a 5-day treatment with ME2136. This study was registered with the Japan Registry of Clinical Trials (jRCT2041200071) on 10 December 2020. Clinical trial registration: This study was registered with the Japan Registry of Clinical Trials (jRCT2041200071) on 10 December 2020.
Identifiants
pubmed: 39460855
doi: 10.1007/s10637-024-01480-w
pii: 10.1007/s10637-024-01480-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Hesketh PJ, Kris MG, Grunberg SM et al (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15(1):103–109
doi: 10.1200/JCO.1997.15.1.103
pubmed: 8996130
Navari RM, Qin R, Ruddy KJ et al (2016) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 375(2):134–142
doi: 10.1056/NEJMoa1515725
pubmed: 27410922
pmcid: 5344450
Hashimoto H, Abe M, Tokuyama O et al (2020) Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21(2):242–249
doi: 10.1016/S1470-2045(19)30678-3
pubmed: 31838011
(2023) NCCN clinical practice guidelines in oncology version 1. Antiemesis. High emetic risk parenteral anticancer agents - acute and delayed emesis prevention. National Comprehensive Cancer Network
Nicol GE, Yingling MD, Flavin KS et al (2018) Metabolic effects of antipsychotics on adiposity and insulin sensitivity in youths: a randomized clinical trial. JAMA Psychiat 75(8):788–796
doi: 10.1001/jamapsychiatry.2018.1088
Seaburg HL, McLendon BM, Doraiswamy PM (2001) Olanzapine-associated severe hyperglycemia, ketonuria, and acidosis: case report and review of literature. Pharmacotherapy 21(11):1448–1454
doi: 10.1592/phco.21.17.1448.34421
pubmed: 11714220
Koller EA, Doraiswamy PM (2002) Olanzapine-associated diabetes mellitus. Pharmacotherapy 22(7):841–852
doi: 10.1592/phco.22.11.841.33629
pubmed: 12126218
Silvestre JS, Prous J (2005) Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. Methods Find Exp Clin Pharmacol 27(5):289–304
doi: 10.1358/mf.2005.27.5.908643
pubmed: 16082416
Aggarwal G, Kamada P, Chari ST (2013) Prevalence of diabetes mellitus in pancreatic cancer compared to common cancers. Pancreas 42(2):198–201
doi: 10.1097/MPA.0b013e3182592c96
pubmed: 23000893
pmcid: 3896296
Shahid M, Walker GB, Zorn SH et al (2009) Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 23(1):65–73
doi: 10.1177/0269881107082944
pubmed: 18308814
(2020) Meiji Seika Pharma Co., Ltd. SYCREST® Sublingual Tablets Drug Product Interview Form Ver.6. pp 28–29
Kinoshita T, Bai YM, Kim JH et al (2016) Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6-week, placebo-controlled study. Psychopharmacology 233(14):2663–2674
doi: 10.1007/s00213-016-4295-9
pubmed: 27271087
pmcid: 4917598
Treatment guide for diabetes 2020–2021: Japan diabetes society, pp 24–33
(2020) Zyprexa® Tablets Drug Product Interview Form Ver.24, pp 75–76